ARTICLE | Company News
Araxis licenses AD 177 to Bioglan
January 16, 2001 8:00 AM UTC
Bioglan (LSE:BGP) and Arakis ( Cambridge, U.K.) will co-develop Arakis's AD 177 to treat psoriasis using BGP's dermal delivery technologies. BGP will receive exclusive global rights to commercialize A...